1 |
Nakamoto Y, Osman M, Cohade C, Marshall LT, Links JM, Kohlmyer S, et al. PET/CT: comparison of quantitative tracer uptake between germanium and CT transmission attenuationcorrected images. J Nucl Med 2002;43:1137-43
|
2 |
Antoch G, Freudenberg LS, Egelhof T, Stattaus J, Jentzen W, Debatin JF, et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 2002; 43:1339-42
|
3 |
Nakamoto Y, Chin BB, Kraitchman DL, Lawler LP, Marshall LT, Wahl RL. Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology 2003;227: 817-24
DOI
ScienceOn
|
4 |
Mawlawi O, Erasmus JJ, Munden RF, Pan T, Knight AE, Macapinlac HA, et al. Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation. Am J Roentgenol 2006;186:308-19
DOI
ScienceOn
|
5 |
Yau YY, Chan WS, Tam YM, Vernon P, Wong S, Coel M, et al. Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error- J Nucl Med 2005;46:283-91
|
6 |
Antoch G, Kuehl H, Kanja J, Lauenstein TC, Schneemann H, Hauth E, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004;230:879-85
DOI
ScienceOn
|
7 |
Mejia AA, Nakamura T, Masatoshi I, Hatazawa J, Masaki M, Watanuki S. Estimation of absorbed doses in humans due to intravenous administration of fluorine-18-fluorodeoxyglucose in PET studies. J Nucl Med 1991;32:699-706
|
8 |
Visvikis D, Costa DC, Croasdale I, Lonn AH, Bomanji J, Gacinovic S, et al. CT-based attenuation correction in the calculation of semi-quantitative indices of [ ]FDG uptake in PET. Eur J Nucl Med Mol Imaging 2003;30:344-53
DOI
|
9 |
Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [ ]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35:1773-82
DOI
ScienceOn
|
10 |
Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? -FDG and CT contrast agents in dual-modality -FDG PET/CT. J Nucl Med 2004;45 Suppl 1:56S-65S
|
11 |
Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Hojgaard L. PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 2005;32:1167-75
DOI
|
12 |
Antoch G, Freudenberg LS, Stattaus J, Jentzen W, Mueller SP, Debatin JF, et al. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. Am J Roentgenol 2002;179:1555-60
DOI
ScienceOn
|
13 |
Beyer T, Antoch G, Bockisch A, Stattaus J. Optimized intravenous contrast administration for diagnostic whole-body -FDG PET/CT. J Nucl Med 2005;46:429-35
|
14 |
Beyer T, Antoch G, Muller S, Egelhof T, Freudenberg LS, Debatin J, et al. Acquisition protocol considerations for combined PET/CT imaging. J Nucl Med 2004;45 Suppl 1:25S-35S
|
15 |
Hubbell JH. Photon mass attenuation and mass energy-absorption coefficients for H, C, N, O, Ar, and seven mixtures from 0.1 keV to 20 MeV. Radiat Res 1977;70:58-81
DOI
|
16 |
Brechtel K, Klein M, Vogel M, Mueller M, Aschoff P, Beyer T, et al. Optimized contrast-enhanced CT protocols for diagnostic whole-body -FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging. J Nucl Med 2006;47:470-6
|
17 |
Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys 1998;25: 2046-53
DOI
ScienceOn
|
18 |
Violante MR, Dean PB. Improved detectability of VX2 carcinoma in the rabbit liver with contrast enhancement in computed tomography. Radiology 1980;134:237-9
DOI
|